Bionano Genomics (BNGO) Net Margin (2017 - 2026)

Bionano Genomics has disclosed Net Margin across 10 years of filings, most recently posting 124.17% for Q1 2026.

• Net Margin for Q1 2026 came in at 124.17%, down 7613.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 109.95% (up 18564.0% YoY), and the FY2025 annual result was 92.59%, up 27281.0% from the prior year.
• Net Margin came in at 124.17% for Q1 2026 at Bionano Genomics, down from 99.77% in the prior quarter.
• In the past five years, Net Margin ranged from a high of 48.04% in Q1 2025 to a low of 1208.05% in Q3 2023.
• The 5-year median for Net Margin is 409.39% (2023), against an average of 383.73%.
• Across the five-year window, Net Margin plunged 76754 bps in 2023 and jumped 61315 bps in 2025, its largest moves.
• Bionano Genomics' Net Margin stood at 470.81% in 2022, then rose by 13 bps to 409.39% in 2023, then surged by 38 bps to 251.9% in 2024, then soared by 60 bps to 99.77% in 2025, then dropped by 24 bps to 124.17% in 2026.
• The last three Net Margin figures came in at 124.17% (Q1 2026), 99.77% (Q4 2025), and 115.42% (Q3 2025), per Business Quant data.